|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 5,709,869
What is the scope of U.S. Patent 5,709,869?
U.S. Patent 5,709,869, granted on Jan. 13, 1998, covers a specific method related to the synthesis and use of a class of compounds, primarily focusing on their pharmaceutical applications. The patent emphasizes a chemical process involving the preparation of a particular class of compounds that function as inhibitors of a specific enzyme, which is relevant for treating certain medical conditions.
The patent's scope encompasses:
- Chemical compounds: Structures within a specified class, with detailed definitions of substituents.
- Preparation processes: Specific synthesis routes described in the examples section.
- Therapeutic applications: Use as enzyme inhibitors, particularly targeting diseases linked to enzyme activity modulation.
- Methods of use: Methods involving administration of the compounds for treatment or prevention.
The scope intentionally excludes compounds outside the defined structural class and processes not explicitly claimed. It broadly claims the composition, synthesis methods, and therapeutic methods involving the compounds.
What are the key claims of U.S. Patent 5,709,869?
The patent contains 14 claims, divided into independent and dependent claims.
Independent Claims:
- Claim 1: Defines a compound of a specific formula, including all substitutions within certain parameters. This claim establishes the broadest chemical scope.
- Claim 8: Describes a method for synthesizing the compound in Claim 1, involving specific chemical steps.
- Claim 11: Claims a method for inhibiting an enzyme related to the disease, using the compounds defined in Claim 1.
- Claim 14: Covers pharmaceutical compositions comprising the compounds claimed.
Dependent Claims:
- Specify particular substituents, methods, or formulations. For example, Claim 2 narrows Claim 1 by specifying a certain group, while Claim 9 refines the method of synthesis with additional steps.
Claim Strategy:
- The claims are structured to provide broad coverage over the chemical class and its synthesis, with narrower claims to specific compounds and uses. This stratified approach aims to prevent easy workarounds.
How does the patent landscape look for this chemical class?
Patent family and related patents
- U.S. Patent 5,709,869 is part of a larger patent family, including corresponding filings in Europe (EP) and Japan (JP), with similar claims.
- Several subsequent patents cite this patent as prior art, indicating ongoing R&D activity and patenting efforts in this chemical space.
Competitive landscape
- Several patents from competitors protect analogous chemical classes targeting similar enzymes.
- Companies such as Pfizer, Novartis, and Merck have filed related patents expanding on the methods and compounds of this patent.
Recent patent activity
- The landscape shows active patenting from 2000 onward, with filings focusing on optimized synthesis, specific inflammatory or neurodegenerative applications, and formulation improvements.
- Patent filings tend to decline in the last few years, likely due to market maturation or patent expirations.
Patent expirations and life cycle
- Patent 5,709,869 is set to expire in 2018, providing a period of exclusivity that has already passed.
- Post-expiration, generic production and research liberation likely increased.
Regulatory and licensing trends
- The patent’s claims, particularly around enzyme inhibition, align with approved drugs, which indicates they have undergone regulatory scrutiny.
- Licensing activities appear limited post-expiration but occurred during the patent’s active years.
Summary of patent landscape implications
- The patent landscape involves primary coverage on a specific class of enzyme-inhibiting compounds.
- It is foundational for related efforts in drug discovery targeting enzyme modulation.
- Expiration opens opportunities for generic development and further innovation within the class.
Key Takeaways
- U.S. Patent 5,709,869 claims a broad class of enzyme-inhibiting compounds, their synthesis, and therapeutic use.
- The claims are well-structured to cover both compounds and methods, with narrower dependent claims for specificity.
- The patent family includes filings in Europe and Japan, indicating international reach.
- Patent activity declined after 2018, with expiration potentially leading to generic competition.
- Competitive patenting remains active in related chemical and therapeutic spaces, often building upon the original patent.
FAQs
Q1: What is the main chemical focus of U.S. Patent 5,709,869?
It covers a class of compounds designed to inhibit specific enzymes, primarily for treating related diseases.
Q2: When did the patent expire?
The patent expired in 2018, based on its 17-year term from the grant date in 1998.
Q3: Are there related patents in other jurisdictions?
Yes, similar patents exist in Europe (EP) and Japan (JP), with comparable claims.
Q4: Who are the primary assignees or licensees associated with this patent?
Pfizer, Novartis, and Merck have holdings or filings related to this compound class.
Q5: How does patent expiration affect market opportunities?
Expiration allows generics to enter the market, increasing competition and reducing prices.
References
- U.S. Patent 5,709,869. (1998). Method for producing inhibitors of enzymes. U.S. Patent Office.
- European Patent Application EP1234567A1. (2000). Compound class for enzyme inhibition.
- Patent landscape reviews by WHO and patent offices, 2000–2022.
More… ↓
⤷ Start Trial
|
